TrialEBioMedicine2019

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial.

Rahim Mohammad Naimi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.